Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abraxis BioScience Inc.

Division of Celgene Corp.
www.abraxisbio.com

Latest From Abraxis BioScience Inc.

Celgene's Partnered Pipeline Delivers Successes And Setbacks

Celgene won the first approval for a drug developed under its aggressive deal-making strategy in 2017 and several potential blockbusters in its partnered pipeline are edging closer to the market. Ozanimod will soon face regulatory approval, but the next-in-line acquired asset GED-0301 had a major setback. Scrip considers the contribution externally derived products have made – and will make – to Celgene’s business.

Deals Business Strategies

Celgene Eases Angst Over Otezla, Sets The Stage For Growth

Celgene reported second quarter sales growth for key assets in its commercial portfolio, including a recovery for Otezla, and prepared investors for a deluge of data in the second half of 2017.

Sales & Earnings Business Strategies

Can A New Formulation Of An Old Drug Get An SPC? European Court To Decide

A case being referred to the Court of Justice of the European Union by the UK High Court is expected to clarify inconsistencies in EU case law as to whether a new formulation of an old substance is eligible for a supplementary protection certificate.

Intellectual Property Legislation

APPOINTMENT ROUND UP: GlaxoSmithKline, Sanofi, Immune Design, Clinigen, Advaxis, Nanobiotix and Kite Pharma

This week's round up includes CEO appointments by GSK, who has appointed Brian McNamara CEO of the company's consumer unit, Clinigen and The Grünenthal Group; and executive appointments by Sanofi, where Alan Main has joined as executive vice president consumer healthcare global business unit, Immune Design, Advaxis, Kite Pharma and Bavarian Nordic.

Appointments
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register